AI Drug Clinical Development Market Opens as Lunit, Neurophet See Revenue Growth
AI-summarised brief · reviewed before publication
Tempus, a leading healthcare AI firm, has partnered with Daiichi Sankyo to accelerate antibody-drug conjugate development using AI and real-world data. The collaboration aims to discover biomarkers and select patients most likely to respond to new therapies, potentially increasing trial success rates. This partnership is seen as a significant milestone in the global AI drug clinical development market, with related revenue from companies like Lunit and Neurophet experiencing rapid growth.